{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:19:01Z","timestamp":1790486341440,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:00:00Z","timestamp":1539302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merrimack Pharmaceuticals"},{"name":"Ipsen"},{"DOI":"10.13039\/100000042","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche"},{"name":"Sanofi-Aventis"},{"DOI":"10.13039\/100005565","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009010","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche"},{"DOI":"10.13039\/100009010","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Serono"},{"name":"TTY Biopharm"},{"name":"OBI Pharma"},{"name":"Polaris"},{"name":"National Institute for Health Research Biomedical Research Centres (NIHR BRC)"},{"DOI":"10.13039\/100011338","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Serono"},{"name":"Sanofi"},{"name":"Merrimack Pharmaceuticals"},{"name":"Medimmune"},{"DOI":"10.13039\/100011338","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merrimack Pharmaceuticals"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ipsen"},{"name":"BMS"},{"DOI":"10.13039\/100009010","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merrimack Pharmaceuticals, Inc."},{"name":"Florian Szardenings of Physicians World Europe GmbH"},{"name":"Shire"},{"name":"Servier"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejca.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T23:04:44Z","timestamp":1541631884000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial"],"prefix":"10.1016","volume":"105","author":[{"given":"Li-Tzong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wang-Gillam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Pin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Bodoky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Shen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle S.","family":"Jameson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Fang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Schwartsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi S.","family":"Braiteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mamlouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2018.09.010_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12029-015-9724-1","article-title":"A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs","volume":"46","author":"Carrato","year":"2015","journal-title":"J Gastrointest Cancer"},{"issue":"19","key":"10.1016\/j.ejca.2018.09.010_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2018.09.010_bib3","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2018.09.010_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl_4","key":"10.1016\/j.ejca.2018.09.010_bib5","first-page":"iv157","article-title":"Appendix 6: cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org\/Guidelines\/Gastrointestinal-Cancers)","volume":"28","author":"Ducreux","year":"2017","journal-title":"Ann Oncol"},{"issue":"10018","key":"10.1016\/j.ejca.2018.09.010_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.010_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1186\/s12885-016-2933-6","article-title":"A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors","volume":"16","author":"Chiang","year":"2016","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.ejca.2018.09.010_bib8","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.010_bib9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","article-title":"A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma","volume":"24","author":"Roy","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.010_bib10","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.ejca.2018.09.010_bib11","first-page":"4187","article-title":"Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11","volume":"51","author":"Kawato","year":"1991","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2018.09.010_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat Nanotechnol"},{"issue":"Suppl_6","key":"10.1016\/j.ejca.2018.09.010_bib13","first-page":"622PD","article-title":"Final results of NAPOLI-1: a phase 3 study of nal-IRI (MM-398) \u00b1 5-fluorouracil and leucovorin (5-FU\/LV) vs 5-FU\/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.010_bib14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/bjc.2017.67","article-title":"Quality-adjusted survival with combination nal-IRI+5-FU\/LV vs 5-FU\/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis","volume":"116","author":"Pelzer","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.09.010_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ctrv.2016.09.001","article-title":"Post-gemcitabine therapy for patients with advanced pancreatic cancer - a comparative review of randomized trials evaluating oxaliplatin- and\/or irinotecan-containing regimens","volume":"50","author":"Vogel","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2018.09.010_bib16","series-title":"US NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) pancreatic adenocarcinoma version 1.2018","first-page":"1","year":"2018"},{"key":"10.1016\/j.ejca.2018.09.010_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.9636","article-title":"Metastatic pancreatic cancer: ASCO clinical practice guideline update","author":"Sohal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.010_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2016.70.1607","article-title":"Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: applicability to clinical situations","volume":"35","author":"Wang-Gillam","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4_Suppl","key":"10.1016\/j.ejca.2018.09.010_bib19","volume":"36","author":"Wang-Gillam","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.010_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/bjc.2013.408","article-title":"A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer","volume":"109","author":"Ko","year":"2013","journal-title":"Br J Cancer"},{"issue":"32","key":"10.1016\/j.ejca.2018.09.010_bib21","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: a randomized phase III study of 5-fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2018.09.010_bib22","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:32Z","timestamp":1760732552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"alternative-id":["S0959804918313807"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}